Scarica l'app Stockscreener
0.6649
0.33%
0.0022
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6627
Aprire:
$0.662
Volume 24 ore:
1.72M
Relative Volume:
1.22
Capitalizzazione di mercato:
$79.98M
Reddito:
-
Utile/perdita netta:
$-93.61M
Rapporto P/E:
-0.3151
EPS:
-2.11
Flusso di cassa netto:
$-71.16M
1 W Prestazione:
+14.05%
1M Prestazione:
-0.82%
6M Prestazione:
-17.49%
1 anno Prestazione:
-39.55%
Intervallo 1D:
$0.66
$0.7169
Intervallo di 1 settimana:
$0.613
$0.7169
Portata 52W:
$0.5062
$1.39
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Confronta IMUX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.6649 | 79.71M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Iniziato | Roth Capital | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
Immunic targets MS market with Phase 3 dataICYMI - Proactive Investors
Can Immunic Inc. stock beat market expectations this quarterTrade Entry Report & AI Driven Stock Price Forecasts - ulpravda.ru
Earnings Update: Will Immunic Inc stock see insider buyingJuly 2025 Drop Watch & Consistent Income Trade Recommendations - moha.gov.vn
Can Immunic Inc. stock maintain operating marginsJobs Report & Consistent Profit Trade Alerts - ulpravda.ru
Will Immunic Inc. stock see insider buyingJuly 2025 Volume & High Accuracy Investment Entry Signals - ulpravda.ru
Why Immunic Inc. (10VA) stock appears on watchlists2025 Buyback Activity & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Immunic Inc. stock keep outperforming rivals2025 Growth vs Value & Reliable Entry Point Alerts - ulpravda.ru
Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital - Defense World
Immunic looks to 2026 data as late-stage MS program advances - Proactive financial news
Immunic CEO on key 2025 highlights and 2026 milestones - Proactive financial news
EQS-News: Immunic AG: Immunic Highlights 2025 Accomplishments and Upcoming Milestones - FinanzNachrichten.de
Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PR Newswire
Immunic Transfers Listing to Nasdaq Capital Market for Compliance - TipRanks
Immunic to transfer listing to Nasdaq Capital Market after bid price non-compliance - Investing.com
Immunic Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy? - Defense World
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements - Investing.com Australia
Immunic appoints Duane Nash as CEO of new subsidiary Gliomic, updates executive agreements By Investing.com - Investing.com South Africa
Immunic, Inc. Announces Executive Role Changes - TradingView — Track All Markets
Immunic (IMUX) Has a New Rating from Chardan Capital - The Globe and Mail
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.
Immunic Earnings Notes - Trefis
Gainers Report: Will Immunic Inc 10VA stock benefit from mergers2025 Fundamental Recap & Reliable Breakout Forecasts - moha.gov.vn
Will Immunic Inc. (10VA) stock benefit from mergersJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Will Immunic Inc. (10VA) stock extend growth storyWeekly Trade Summary & AI Based Buy/Sell Signal Reports - DonanımHaber
Why Immunic Inc. (10VA) stock stays resilientQuarterly Profit Review & Daily Chart Pattern Signals - DonanımHaber
Will Immunic Inc. stock outperform international peersStock Surge & Intraday High Probability Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Immunic (IMUX) - The Globe and Mail
Immunic Inc (IMUX)’s stock performance: a year in review - uspostnews.com
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
683 Capital Management LLC Reduces Stake in Immunic, Inc. $IMUX - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts - Defense World
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Analysts - MarketBeat
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Immunic Inc - GuruFocus
How does Immunic Inc (IMUX) change from a tortoise to a hare? - setenews.com
Immunic’s long-term treatment hope for multiple sclerosis – ICYMI - Proactive financial news
Operating income of Immunic, Inc. – HAM:10VA - TradingView
Will Immunic Inc. stock deliver better than expected guidanceRisk Management & Real-Time Buy Signal Alerts - Newser
How risky is Immunic Inc. stock nowJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Will Immunic Inc. (10VA) stock return to pre crash levels2025 Fundamental Recap & Consistent Profit Alerts - Newser
How supply chain issues affect Immunic Inc. stockMarket Activity Recap & Weekly Sector Rotation Insights - Newser
Why Immunic Inc. (10VA) stock is a strong analyst pickPortfolio Gains Summary & Technical Pattern Alert System - Newser
Can Immunic Inc. (10VA) stock withstand sector downturnsTrade Exit Summary & Real-Time Buy Zone Alerts - Newser
Is Immunic Inc. stock near bottom after declineOil Prices & Daily Momentum Trading Reports - Newser
How Immunic Inc. stock performs in stagflation2025 Investor Takeaways & Target Return Focused Picks - Newser
Immunic marks International Day of Persons with Disabilities with hope for MS sufferers - Proactive financial news
What consensus target says about Immunic Inc. (10VA) stockWeekly Risk Summary & Safe Capital Growth Stock Tips - Newser
Why Immunic Inc. stock is considered a top pickPortfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Will Immunic Inc. (10VA) stock outperform Dow JonesTrade Analysis Summary & Technical Confirmation Trade Alerts - Newser
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Will Immunic Inc. (10VA) stock outperform global peers2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):